Dermata Therapeutics -CW26DRMAWPreferred / convertible
13F holders, Q3 2024 (September 30)3holders −1
0new positions
1sold out
$1.21avg. 13F price*
At the end of Q3 2024, 3 institutions reported holding Dermata Therapeutics -CW26 (DRMAW) in their 13F filings, down 1 from Q2 2024. 0 opened new positions and 1 sold out. The largest holders were Boothbay Fund Management, LLC ($20K), UBS Group AG ($42) and Bank of America Corp. ($1).
- Company
- Dermata Therapeutics -CW26
- CUSIP
- 249845116
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 1 | $420 |
All 13F filers, Q2 2024 → Q3 2024: 30,900 shares sold, net −30,900 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| Boothbay Fund Management, LLC | — | No change | 12,000 | $20K |
| UBS Group AG | — | Reduce -15.9% | 4,242 | $42 |
| Bank of America Corp. | — | Reduce -50.0% | 100 | $1 |
"% of holder's portfolio" is DRMAW's weight in each manager's 13F, not the share of Dermata Therapeutics -CW26 the manager owns.